Biosimilar Landscape

Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options.

As featured in the 2023 Biosimilars Report, here are highlights of some of the most noteworthy milestones in the development and adoption of biosimilars from ...

Biologics and Biosimilars Landscape: IP, Policy, and Market ...

Prior to its approval, Tofidence™ was subject to BPCIA litigation filed by Genentech against Biogen and Bio-Thera in July 2023. The parties ...

Understanding the Biosimilar Landscape - Univera For Business

Biosimilars are biologic drugs that are “highly similar” and “clinically equivalent” to another biologic “reference” product already approved by the US Food ...

The regulatory landscape of biosimilars: WHO efforts and progress ...

USA-approved filgrastim as the first biosimilar product in 2015. Since then a total of 23 biosimilars have been approved. Three insulin products (2 glargine and ...

The biosimilars market will grow exponentially in 2023 as potentially 10+ biosimilar launches are anticipated to compete with Humira®.

Biosimilar Drugs & Products - McKesson

... biosimilar adoption. As the biosimilar landscape continues to evolve, we can expect to see more biosimilar treatment options for more conditions. McKesson ...

Current Landscape of Biosimilar Use in US Healthcare Space

Dr Humphreys drives a conversation scoping the biosimilar landscape and available treatment options.

Evolving Biosimilar Landscape

Learn how biosimilars and biologics have been used to treat different life-threatening & chronic diseases, such as cancers and diabetes, & their potential ...

Biosimilars Report | Cardinal Health

In this report, we explore how biosimilars are living up to their promise of increased affordability and accessibility for the US healthcare industry.

Biosimilars - FDA

FDA approved biosimilars are safe, effective treatment options. Biosimilars may provide more treatment options, increase access to ...

The launch of the first biosimilar of Humira (adalimumab) last year was a major opportunity to increase patient access to, and lower the ...

The current status of the biosimilars landscape in China

As of September 2023, China has approved a total of 31 antibody-based biosimilars (see Table 1). These include 10 versions of Bevacizumab, 7 versions of ...

Defining Value With a Changing Biosimilar Landscape

Mariam Alboustani, PharmD, discusses the one published example of a switching study and the implications of interchangeability for pharmacists, as well as ...

An Overview of Regulatory Approvals by the EMA and FDA - PMC

Biosimilar medicines expand the biotherapeutic market and improve patient access. This work looked into the landscape of the European and US ...

Evolution of Auto-Substitution in Biosimilar Landscape

Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.

The changing landscape of biosimilars in rheumatology

For patients, biosimilars will increase affordability of treatment options and improve accessibility. Understandably, evidence-based information is needed to ...

Overview of the Biosimilar Landscape - Pharmacy Times

Biosimilars, which at the most simplistic level can be thought of as a type of generic option for a biologic, offer an opportunity to help ...

The emergence of biosimilars has provided promise of increased cost-savings and increased patient accessibility to biologics. However, this promise has not ...

An Overview of Regulatory Approvals by the EMA and FDA

The Biosimilar Landscape: An ... An update on the adalimumab biosimilar landscape following the approval of the first high-concentration biosimilar.